Altimmune Appoints Dr. Scott Harris as Chief Medical Officer

Ticker: ALT · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1326190

Altimmune, Inc. 8-K Filing Summary
FieldDetail
CompanyAltimmune, Inc. (ALT)
Form Type8-K
Filed DateFeb 25, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, personnel, cmo

Related Tickers: SRPT

TL;DR

Altimmune just hired a new CMO, Dr. Scott Harris, from Sarepta. Big move for their clinical strategy.

AI Summary

Altimmune, Inc. announced on February 24, 2025, the appointment of Dr. Scott Harris as Chief Medical Officer, effective immediately. Dr. Harris previously served as Executive Vice President and Chief Medical Officer at Sarepta Therapeutics, Inc. The company also reported on compensatory arrangements for its officers.

Why It Matters

The appointment of a new Chief Medical Officer can signal a strategic shift or renewed focus on clinical development and regulatory pathways for Altimmune's drug candidates.

Risk Assessment

Risk Level: medium — The appointment of a new executive, especially a CMO, can introduce changes in strategy or execution, carrying inherent risks.

Key Players & Entities

  • Altimmune, Inc. (company) — Registrant
  • Dr. Scott Harris (person) — Newly appointed Chief Medical Officer
  • Sarepta Therapeutics, Inc. (company) — Dr. Harris's previous employer
  • February 24, 2025 (date) — Effective date of appointment

FAQ

Who has been appointed as the new Chief Medical Officer of Altimmune, Inc.?

Dr. Scott Harris has been appointed as the new Chief Medical Officer of Altimmune, Inc.

When was Dr. Scott Harris's appointment effective?

Dr. Scott Harris's appointment was effective February 24, 2025.

What was Dr. Scott Harris's previous role?

Dr. Scott Harris previously served as Executive Vice President and Chief Medical Officer at Sarepta Therapeutics, Inc.

What other information is included in this 8-K filing?

This 8-K filing also includes information regarding the election of directors and compensatory arrangements of certain officers.

What is Altimmune, Inc.'s primary business?

Altimmune, Inc. is in the business of Pharmaceutical Preparations, SIC code 2834.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 by Dr. Scott Harris regarding Altimmune, Inc. (ALT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.